Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today reported unaudited financial results for the first quarter ended March 31, 2011.
Highlights
- Total revenue was RMB482.2 million (US$73.6 million) for the first quarter of 2011, which represented an increase of 5.1% from RMB458.7 million for the same period in 2010.
- Income from operations was RMB29.6 million (US$4.5 million) for the first quarter of 2011, compared to RMB30.9 million for the same period in 2010.
- Net income attributable to Simcere was RMB27.9 million (US$4.3 million) for the first quarter of 2011, which represented an increase of 36.2% from RMB20.5 million for the same period in 2010.
- Gross margin for the first quarter of 2011 was 83.9%, compared to 79.7% for the same period in 2010.
Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group commented, "In the first quarter of 2011, Simcere maintained strong gross margins, while realizing healthy growth in both revenue and net income attributable to Simcere. As a result of the progress of our sales team reorganization, we saw an encouraging upward trend in sales of our anti-tumor drugs, including Endu, Sinofuan and Jiebaishu."
Mr. Ren added, "Shanghai Celgen recently received new drug registration approval for Qiangke, its Recombinant Human TNF Receptor-IgG Fusion Protein for Injection, and we are confident that this drug will address a wide market demand when it becomes available."
In 2009, Simcere acquired approximately 35% of the equity of Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen").
2011 First Quarter Financial Results
Total revenue for the first quarter of 2011 was RMB482.2 million (US$73.6 million), which represented an increase of 5.1% from RMB458.7 million for the same period in 2010.
Revenue from edaravone injection products under the brand names Bicun and Yidasheng totaled RMB188.7 million (US$28.8 million) for the first quarter of 2011, which was 39.1% of the Company's product revenue for the first quarter of 2011, an increase of 9.0% from RMB173.2 million for the same period in 2010.
Revenue from Endu, the Company's patented anti-cancer biotech product, amounted to RMB49.6 million (US$7.6 million) in the first quarter of 2011, which was 10.3% of the Company's product revenue for the first quarter of 2011, an increase of 32.8% from RMB37.4 million for the same period in 2010.
Revenue from Sinofuan, a 5-FU sustained release implant for the treatment of cancer, amounted to RMB29.4 million (US$4.5 million) for the first quarter of 2011, which was 6.1% of the Company's product revenue for the first quarter of 2011, an increase of 15.9% from RMB25.3 million for the same period in 2010.
Revenue from other branded generic products including Zailin and Yingtaiqing amounted to RMB214.4 million (US$32.7 million), which was 44.5% of the Company's product revenue for the first quarter of 2011, an increase of 10.0% from RMB194.9 million for the same period in 2010.
Gross margin for the first quarter of 2011 was 83.9%, increasing from 79.7% for the same period in 2010.
Research and development expenses for the first quarter of 2011 totaled RMB42.6 million (US$6.5 million), which represented an increase of 39.2% from RMB30.6 million for the same period in 2010. This increase was primarily due to increased investment in research and development. As a percentage of total revenue, research and development expenses were 8.8% for the first quarter of 2011, compared to 6.7% for the same period in 2010.
Sales, marketing and distribution expenses for the first quarter of 2011 were RMB264.4 million (US$40.4 million), which represented an increase of 11.6% from RMB236.9 million for the same period in 2010. As a percentage of total revenue, sales, marketing and distribution expenses were 54.8% for the first quarter of 2011, compared to 51.6% for the same period in 2010. This increase was primarily due to the expansion of our sales team and higher promotion expenses for new-to-market drugs.
General and administrative expenses were RMB68.1 million (US$10.4 million) for the first quarter of 2011, which represented an increase of 1.3% from RMB67.2 million for the same period in 2010. As a percentage of total revenue, general and administrative expenses decreased to 14.1% for the first quarter of 2011 from 14.7% for the same period in 2010.
Share-based compensation expense, which was allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the employee was assigned to perform, totaled RMB7.3 million (US$1.1 million) for the first quarter of 2011. Share-based compensation expenses for the first quarter of 2010 were RMB8.0 million.
Income from operations was RMB29.6 million (US$4.5 million) for the first quarter of 2011, compared to RMB30.9 million for the same period in 2010.
Income tax expense for the first quarter of 2011 was RMB5.1million (US$0.8 million), compared to RMB1.3 million for the same period in 2010.
Net income attributable to Simcere was RMB27.9 million (US$4.3 million) for the first quarter of 2011, compared to RMB20.5 million for the same period in 2010. Net margin was 5.8% for the first quarter of 2011, compared to 4.5% for the first quarter of 2010.
Basic and diluted earnings per American Depository Share ("ADS") for the first quarter of 2011 were RMB0.52 (US$0.08) and RMB0.50 (US$0.08) respectively. One ADS represents two ordinary shares of the Company.
As of March 31, 2011, the Company had cash, cash equivalents and restricted cash of RMB236.0 million (US$36.0 million), compared to RMB278.7 million as of December 31, 2010.
New trials show promise for immune checkpoint blockers in early-stage lung cancer